Roche’s Perjeta for Breast Cancer Wins Approval

Roche Holding AG’s personalized drug treatment for a fast-growing type of breast cancer won approval from U.S. regulators.

Perjeta, chemically known as pertuzumab, is designed to work with the Basel, Switzerland-based company’s Herceptin and chemotherapy to attack breast cancer that has spread in patients who have a certain gene mutation. The Food and Drug Administration today cleared Perjeta for consumer use, Roche’s Genentech unit said in a statement.

(Corrects drug spelling in headline, second paragraph of story published June 8.)
Before it's here, it's on the Bloomberg Terminal. LEARN MORE